Trial Profile
FAT GENE EXPRESSION IN OVERWEIGHT AND OBESE PATIENTS WITH PERSISTENTLY ACTIVE RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT AND CLINICAL RESPONSE
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2018
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacodynamics
- 16 Feb 2018 Status changed from recruiting to discontinued.
- 07 Apr 2015 New trial record